There’s no way around it: offtake deals are essential for scaling Europe’s bioeconomy.
We explain how offtakes drive scaling, reviewing recent deals in Europe and why we could see more of them in the near future.
Why offtakes matter
For the bio-based industries, competing with petrochemicals means scaling up. This means more raw materials and more manufacturing capacity – factors that would push down production costs and ultimately consumer prices.
Yet bio-based producers are only willing to expand if they are sure demand can absorb output. For them, the question is whether there are enough customers that will make capacity investments worthwhile.
Offtakes drive scale by eliminating this uncertainty. They are essentially bulk orders: a customer requests a certain volume of a biomaterial, usually over a specified period.
Often, offtakes are signed even before the manufacturer has the capacity to fulfil the order.
This gets to the heart of why offtakes are key to scaling success. They offer the financial security that producers need befocommitting to new production lines. As guarantors of demand, offtakes assure investors that assets will not be left stranded.
By locking in stable revenue and cash flow, offtakes can be a life-line for a small start-up looking to move from R&D to commercial production. Yet larger bio-based producers also find these deals valuable too.
For established bio-producers, a major offtake can make new capacity investments financially viable. A brand new plant becomes easier to justify to shareholders when there’s a customer waiting to snap up half its output. They can also help increase a company’s market share.
Offtakes can have non-financial benefits for bio-based producers too. For example, a large customer can offer a smaller producer access to their R&D capacity. Offtakes can also bolster a firm’s visibility through association with a large customer, increasing their chance of securing further deals.
A classic offtake for bioplastic
With its long-term contract and large volumes, Citroniq and Vinmar’s recent offtake is a classic example of a deal that drives scale by injecting certainty.
In March 2026, global polymer trader Vinmar signed a 15-year binding deal to buy 300, 000 tonnes per year of corn-based polypropylene (PP) from Swiss firm Citroniq. The volumes will come from Citroniq’s Nebraska plant once it enters production in 2029.
This is a major commitment both in terms of product volume and time-span. It demonstrates just how crucial offtakes can be for business planning and market balance for years to come.
Offtakes this big also reflect market sentiment: when legacy plastics companies enter bio-based deals this expansive, it shows that even petrochemicals players are expecting renewables demand to keep growing over the long term.
Avantium strikes twice
Renewable chemistry company Avantium has been busy on the offtake front too, signing two since last August.
Its first deal was with cold-pressed juices from Dutch producer Hoofesteger. The conditional offtake signed last August will see Avantium’s bio-based PEF used in its juice bottles.
The Avantium-Hoofesterger deal shows how offtakes can knit large corporate entities together into supply relationships capable of taking bio-based products mainstream.
Hoogesteger sells its juices through the Netherlands’ largest supermarket chain, Albert Heijn, meaning the deal could get bio-based plastics into consumer baskets all around the country.
Avantium’s other recent conditional off-take was signed last July with Plixxent, a leading European supplier of industrial polyurethane. Plixxent is expected to purchase Avantium’s bio-based foam for use in insulation materials for buildings.
The deal is a sign of the times: it will position Plixxent to capitalise on major trends re-shaping Europe’s building industry. The EU’s sustainable building regulations and an incoming wave of renovation in the bloc is set to boost demand for lower-carbon construction materials like bio-based foam.
Three-year bio-based textile deal
Offtake agreements are usually an indicator that a startup has finally exited the R&D stage and is well on the way to becoming an industrial producer.
We are seeing this lab-to-industry transition happen in real time for the bio-based pigments and dye industry. Startups in the space have been attracting venture capital in recent years, but now, some are starting to get their first commercial orders.
One of them is Danish synbio company Octarine Bio, which signed a deal in August last year with Portuguese textile firms Impetus Group, Acatel Acabamentos Têxteis S.A., and Positive Materials.
The three-year offtake agreement is for the supply and utilisation of pigments and dyes created by Octarine Bio. According to the co-CEO of Positive Materials, Elsa Parente, the deal is valuable because it will allow the companies to “focus on practical integration—not just experimentation.”
What is striking about this deal is that it contains an agreement to validate industrial production processes for Ocatine’s dyes. The fact that multiple companies are supporting industrial validation for such a young product signals the confidence that industry has in Ocatrine’s IP.
This is a classic example of how offtakes go beyond securing revenue – they can help early firms access the capital and know-how they need to make that first leap into industrial production.
Industry wants more
There is a direct correlation between the number of bio-based offtakes happening and the level of private finance flowing into the bioeconomy. This is because private investors know that offtakes are a powerful indicator of potential.
For European commercial banks, a key criteria in deciding whether to lend to a bio-based project is whether it has secured a long-term offtake contract. They are proxies for financial viability, signalling sustained demand – something that is essential for investors in emerging markets like biochemicals and biomaterials.
Yet despite their value, Europe’s producers agree there aren’t enough offtakes happening in the bioeconomy right now. The reason for this is simple: biochemicals and biomaterials are usually more expensive than fossil-based products.
There are several mismatches happening here. First and most obviously, environmental damage is not priced into products. The more cost-effective options are also less sustainable options.
Then there is a mismatch between bio-based producers and industry consumers: for bio-based producers, offtakes are a key way to mitigate financial risk. For buyers, however, the cost of biomaterials represent a source of risk.
The importance of offtakes for attracting financing, coupled with the difficulty in obtaining them, sets up a frustrating chicken-and-egg dilemma. Without private financing, demonstrating a production process at industrial scale is harder. Without successful demos, attracting offtakes deals from customers is difficult, in turn weakening their chances of getting financing.
Breaking out of this cycle ultimately depends on policy from the very top. Luckily, the EU is moving quicker than most on this front, pushing out legislation that imposes costs on buying and using less sustainable materials.
Offtakes needed upstream
Yet even if bio-based offtakes deals were to explode tomorrow, the European bioeconomy would still have a problem: a lack of basic raw materials to fulfil all the orders.
Europe’s lack of a reliable feedstock supply comes down to a lack of offtakes at the upstream, where farmers sell biomass to industry. Right now, European markets for raw biomass feedstock are fragmented. Buyers tend to be small producers and even then, they tend to switch between various feedstocks.
Offtakes between farmers and industry would help. By guaranteeing farmers a certain level of demand for their agro-waste and other renewable raw materials, they can begin to produce a reliable flow of biomass.
The ripple effects of feedstock offtakes would be substantial. A steady output of biomass from European farms would eliminate price fluctuations all down the bio-based supply chain, benefiting downstream processors and producers.
Take-off for offtakes?
While the high cost of renewable materials and feedstocks have so far capped bio-based offtakes in Europe, things are changing quickly.
Economic and regulatory pressures are converging in ways that should boost offtake deals in the near future.
The Iran war’s historic disruptions to the petroleum supply chains means fuel and petrochemicals prices are rising fast. Damage to oil infrastructure from the war could also mean elevated prices for years. This means the price gap between petrochemicals and renewables is narrowing.
What’s more, the Iran war has proven to governments and companies alike that the fragility of long petroleum-based supply chains. Investing in renewable materials has never looked more strategic. Over the next 12 months, as industry adjusts to the new normal, we could see an uptick in offtakes as producers invest in renewable supply chains.
Legislative changes also mean companies that sell to the EU will be reaching for lower-carbon materials.
European legislation on toxic forever chemicals, for example, has tightened since the start of this year. Over in fashion retail, the bloc’s new EPR laws are taxing hard-to-recycle, eco-toxic materials.
Once regarded as a nice-to-have, industry is increasingly seeing renewable materials as strategic investments. In this climate, bio-based offtakes could become an increasingly attractive way of locking in supply security.
The post Why Europe’s bioeconomy needs an offtake boom appeared first on World Bio Market Insights.
